Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France
Author:
Affiliation:
1. HEVA HEOR, Lyon, France;
2. Roche France SAS, Boulogne-Billancourt, France;
3. F. Hoffmann-La Roche Limited, Basel, Switzerland;
4. Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France
Publisher
Informa UK Limited
Subject
Health Policy
Link
https://www.tandfonline.com/doi/pdf/10.1080/13696998.2020.1718156
Reference23 articles.
1. Cancer mortality in Europe in 2015 and an overview of trends since 1990
2. INCa. Les cancers en France. Edition 2015. Avril; 2016.
3. HAS; INCa. Guide du parcours de soins. Cancers broncho-pulmonaires. Juillet; 2013.
4. Évolution en 10ans du cancer bronchique non à petites cellules en fonction du sexe. Résultats de l’étude KBP-2010-CPHG du Collège des pneumologues des hôpitaux généraux
5. Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study)
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cost-Effectiveness of Plasma Microbial Cell-Free DNA Sequencing When Added to Usual Care Diagnostic Testing for Immunocompromised Host Pneumonia;PharmacoEconomics;2024-07-02
2. Therapeutic effects of computerized tomography (CT)-guided percutaneous microwave ablation on malignant lung tumors;Indian Journal of Experimental Biology;2023-09-29
3. Sensitivity Analysis in Economic Evaluations of Immuno-Oncology Drugs: A Systematic Literature Review;Value in Health Regional Issues;2023-09
4. Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer;Pharmaceuticals;2022-04-18
5. Cost–effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan;Future Oncology;2022-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3